Three months have passed since the World Health Organization (WHO) declared coronavirus disease 19 (COVID-19) as a pandemic on March 11, 2020. Due to the high infection rates and occurrence of severe and fatal cases, the search for effective drugs to treat and control the COVID-19 pandemic has been prioritized by health and political authorities. Antimalarials, well-known for their use in dermatology and rheumatology, are one of the medications with the largest - albeit limited - scientific background warranting their use in the COVID-19 treatment protocols. Hydroxychloroquine (HCQ) has been used for the treatment of COVID-19 in 50 patients in our and other centres in several countries with encouraging results. However, recent studies disprove the real effectiveness of this drug, either alone or when combined with macrolides. As a result, the World Health Organization has discouraged the use of HCQ in the treatment and prevention of COVID-19. Herein we report our experience in the use of hydroxychloroquine for COVID-19 treatment. This article is protected by copyright. All rights reserved.

Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association / Diotallevi, F; Campanati, A; Radi, G; Luchetti, M M; Benfaremo, D; Tagliati, C; Simonetti, O; Offidani, A. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - STAMPA. - 93:1(2021), pp. 5-7. [10.1002/jmv.26322]

Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association

Campanati, A;Radi, G;Luchetti, M M;Benfaremo, D;Tagliati, C;Simonetti, O;Offidani, A
2021-01-01

Abstract

Three months have passed since the World Health Organization (WHO) declared coronavirus disease 19 (COVID-19) as a pandemic on March 11, 2020. Due to the high infection rates and occurrence of severe and fatal cases, the search for effective drugs to treat and control the COVID-19 pandemic has been prioritized by health and political authorities. Antimalarials, well-known for their use in dermatology and rheumatology, are one of the medications with the largest - albeit limited - scientific background warranting their use in the COVID-19 treatment protocols. Hydroxychloroquine (HCQ) has been used for the treatment of COVID-19 in 50 patients in our and other centres in several countries with encouraging results. However, recent studies disprove the real effectiveness of this drug, either alone or when combined with macrolides. As a result, the World Health Organization has discouraged the use of HCQ in the treatment and prevention of COVID-19. Herein we report our experience in the use of hydroxychloroquine for COVID-19 treatment. This article is protected by copyright. All rights reserved.
2021
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/293207
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact